VTCN1, or V structural domain-containing T cell activation suppressor 1, is a membrane-bound protein belonging to the B7 family. It is expressed in a variety of cell types, including tumour cells and immune cells.The mechanism of action of VTCN1 involves the regulation of T-cell activation and proliferation, and may affect T-cell receptor (TCR)-mediated signalling pathways through interactions with other members of the B7 family. In addition, VTCN1 may promote tumour cell invasion and metastasis, as well as tumour angiogenesis, in the tumour microenvironment.
VTCN1 expression is abnormally elevated in a wide range of tumours and significantly correlates with poor patient prognosis. It may play an important role in tumour immune escape and metastasis, and is therefore considered a potential target for tumour therapy. Meanwhile, the expression level of VTCN1 has also been used as a biomarker for detecting the condition of tumour patients and therapeutic effects, which has an important clinical application prospect.
VTCN1 Antibody (CSB-PA13005A0Rb)
Validated Data
Immunofluorescence staining of Hela cells with CSB-PA13005A0Rb at 1:66, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
IHC image of CSB-PA13005A0Rb diluted at 1:100 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
The following VTCN1 reagents supplied by CUSABIO are manufactured under a strict quality control system. Multiple applications have been validated and solid technical support is offered.
VTCN1 Antibodies for Homo sapiens (Human)
Code | Product Name | Species Reactivity | Application |
---|---|---|---|
CSB-PA13005A0Rb | VTCN1 Antibody | Human | ELISA, IHC, IF |
CSB-PA594088 | VTCN1 Antibody | Human,Mouse,Rat | ELISA,IHC |
CSB-PA350067 | VTCN1 Antibody | Human,Mouse,Rat | ELISA,IHC |
CSB-PA017573 | VTCN1 Antibody | Human,Mouse,Rat | ELISA,IHC |
VTCN1 Proteins for Rattus norvegicus (Rat)
Code | Product Name | Source |
---|---|---|
CSB-YP700510RA CSB-EP700510RA CSB-BP700510RA CSB-MP700510RA CSB-EP700510RA-B |
Recombinant Rat V-set domain-containing T-cell activation inhibitor 1 (Vtcn1) | Yeast E.coli Baculovirus Mammalian cell In Vivo Biotinylation in E.coli |
VTCN1 Proteins for Mus musculus (Mouse)
Code | Product Name | Source |
---|---|---|
CSB-YP742524MO CSB-EP742524MO CSB-BP742524MO CSB-EP742524MO-B |
Recombinant Mouse V-set domain containing T-cell activation inhibitor 1 (Vtcn1) | Yeast E.coli Baculovirus In Vivo Biotinylation in E.coli |
VTCN1 Proteins for Homo sapiens (Human)
Code | Product Name | Source |
---|---|---|
CSB-YP801822HU CSB-BP801822HU CSB-MP801822HU CSB-EP801822HU-B |
Recombinant Human V-set domain-containing T-cell activation inhibitor 1 (VTCN1), partial | Yeast Baculovirus Mammalian cell In Vivo Biotinylation in E.coli |
CSB-EP801822HUe0 | Recombinant Human V-set domain-containing T-cell activation inhibitor 1 (B7H4), partial | E.coli |
CSB-EP801822HU | Recombinant Human V-set domain-containing T-cell activation inhibitor 1 (B7H4), partial | E.coli |
VTCN1 ELISA Kit for Homo sapiens (Human)
Code | Product Name | Sample Types | Sensitivity |
---|---|---|---|
CSB-E15013h | Human B7-H4 ELISA Kit | serum, plasma, cell culture supernates, tissue homogenates | 1.95 ng/mL |